Oncology CME

The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 Credits^TM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

The BoardVitals Hematology and Oncology CME Review also features:

• Quick and Convenient CME
• Computer, phone, and tablet access
• Constantly updated up-to-date questions
• Questions that are targeted specifically to the exam
• Online CME tracker
• 100% Pass Guarantee
• Statistical comparison to other Hematology and Oncology test-takers (Nationally)

After completing this activity, you should be able to:

• Make a diagnosis
• Order and interpret results
• Assess risk, determine prognosis, and apply principles from epidemiologic studies
• Describe the underlying pathophysiology of disease and basic science knowledge

Target Audience: Hematologists and Oncologists

The AudioDigest CME + CE + MOC Oncology Platinum Membership is our most comprehensive plan available. Get unlimited access to every lecture in our library across all specialties, including over 4,000 evidence-based audio lessons and written summaries with suggested readings and test questions certified for CME, CE, and MOC credits across 15 specialties.

Maximize your CME allowance with MDCalc and get up to a $3,500 bonus gift card of your choice. Earn AMA PRA Category 1 Credits^TM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

Target Audience: Hematologists

In this online, self-learning activity:

Multiple myeloma (MM) is the most common hematologic malignancy after non-Hodgkin lymphoma, with an incidence of over 34,000 and an annual mortality rate of over 12,000. MM-induced osteocyte apoptosis facilitates MM cell survival, and patients with MM are at high risk for bone disease. Osteolytic lesions are reported in up to four out of five newly diagnosed with MM, and throughout their disease course, up to 90% of patients will eventually develop bone lesions. The presence of bone lesions increases MM patient risk for skeletal-related events (SREs), such as fractures, spinal cord compression, or need for surgery or radiotherapy. Bone disease and SREs can have serious consequences in MM, leading to worsened quality-of-life and prospects for survival. Patients who experience fracture after MM diagnosis have a two-fold increased risk of death relative to those who do not experience fracture. Yet bone disease frequently goes untreated in patients with MM, suggesting that clinicians are not familiar with the serious effects of MM.

Activity Description / Statement of Need:

In this online, self-learning activity:

Graft-versus-host disease (GvHD) is an immune-mediated response that occurs in recipients of allogenic hematopoietic cell transplantation (HCT). GvHD can be further categorized into acute and chronic cases. Maculopapular rash, follicular erythema, epidermolysis, are common manifestations of acute GvHD, in addition to liver and gastrointestinal dysfunction such as hyperbilirubinemia, nausea, and diarrhea. This activity focuses on chronic GvHD, which has more extensive multi-organ involvement including the liver, eyes, mouth, lungs, skin, genitalia, and gastrointestinal tract.

Target Audience:

The following HCPs: hematologists and oncologists; nurse practitioners, physician assistants, and pharmacists who specialize in oncology; and those who otherwise commonly care for or clinically encounter patients with GVHD.

Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

Pricing Options

• 6 Month subscription: All 6,339 CME Activities – $249 per 6 months
• Annual subscription: All 6,339 CME Activities – $349 per 1 year
• Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever – $1999

Key Topics in Oncology CME

The Brigham and Dana-Farber Board Review and Comprehensive Update in Oncology is an online CME course designed to update knowledge and improve management strategies. This collection of case-based presentations — presented by a distinguished faculty of experts — will help enhance patient care while you prep for your board exam. It’s continuing medical education that helps you to:

• Apply recommended oncology guidelines in clinical practice
• Perform differential diagnosis of complex oncologic disorders
• Identify and apply current therapeutic options for oncologic disorders
• Evaluate and interpret up-to-date literature relevant to oncology
• Illustrate knowledge of pathophysiology as it applies to management of oncology disorders
• Apply knowledge gained to the ABIM certification/recertification oncology examinations

This program is also available as part of the combined Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology CME course found here.

Activity Description / Statement of Need:
In this online, self-learning activity:

Systemic mastocytosis (SM) is a heterogeneous group of disorders caused by proliferation of abnormal clonal mastocytes, which accumulate in the skin and/or other organ systems. Mastocytosis, including SM, was reclassified as a distinct disease subtype in 2016, when the World Health Organization (WHO) removed mastocytosis from the myeloproliferative neoplasm (MPN) group. The WHO defines 5 SM subtypes, ranging from indolent SM, which is associated with mild symptoms and near-normal life expectancy, to mast cell leukemia, which is an aggressive hematologic malignancy associated with median survival of less than 1 year.

Target Audience:
HCPs including: hematology/oncology specialists, allergists, and clinical immunologists, dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in those areas of specialty; and any other healthcare professionals with an interest in or who may clinically encounter patients with systemic mastocytosis.